Singapore, August 01, 2020: (ACN Newswire) - Made-in-Singapore cancer drug, ETC-159, has achieved a new developmental milestone in achieving "First…
Tokyo, September 29, 2019: Eisai Co., Ltd. announced today that a series of abstracts will be presented during the European…
For LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination Treatment as Potential First-Line Treatment of Patients with Advanced Unresectable Hepatocellular Carcinoma Not…
In Combination with KEYTRUDA as Therapy for Previously Treated Patients with Advanced and/or Metastatic non-MSI-H/pMMR Endometrial Carcinoma Tokyo, August 05,…